Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Ulcerative Colitis
Interventions: Ontamalimab, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 16 Years to 81 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 94
States / cities: Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 80 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine Hydrochloride, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Excessive Daytime Sleepiness, Narcolepsy
Interventions: Placebo, PF-03654746; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more

Conditions: Alcohol Use Disorders
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 65 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Patients, Resistant Hypertension
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Birmingham, Alabama • North Hollywood, California • Atlantis, Florida + 4 more

Conditions: Dry Eye
Interventions: 0.25% Tanfanercept Ophthalmic Solution, Placebo; Drug
Lead sponsor: HanAll BioPharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Phoenix, Arizona • Glendale, California • Newport Beach, California + 7 more

Conditions: Tobacco Use Disorder
Interventions: Paroxetine, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bacterial Vaginosis
Interventions: 0.5% SPL7013 Gel, 1.0% SPL7013 Gel, 3.0% SPL7013 Gel, Placebo Gel; Drug · Other
Lead sponsor: Starpharma Pty Ltd; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Phoenix, Arizona • Denver, Colorado • Las Vegas, Nevada + 2 more

Conditions: Brain Death, Organ Donor, Pulmonary Edema
Interventions: Albuterol, Saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 14 Years and older
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Oakland, California

Conditions: Generalized Anxiety Disorder
Interventions: Placebo, DT120; Other · Drug
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more

Conditions: Safety and Tolerability in Healthy Volunteers
Interventions: VLX-1005, Placebo; Drug
Lead sponsor: Veralox Therapeutics; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
Interventions: Roflumilast, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 2,354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 217
States / cities: Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more

Conditions: Hyponatremia
Interventions: lixivaptan, Placebo; Drug
Lead sponsor: CardioKine Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 102
States / cities: Birmingham, Alabama • Mobile, Alabama • Bakersfield, California + 82 more

Conditions: Systemic Lupus Erythematosus
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more

Conditions: Chronic Idiopathic Constipation
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Anniston, Alabama • Anaheim, California • DeLand, Florida + 8 more

Conditions: Alcohol Use Disorder (AUD)
Interventions: Zonisamide, Placebo; Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Knee Osteoarthritis
Interventions: Micronized dHACM, Saline; Biological · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 14 more

Conditions: Sensitivity, Contact
Interventions: ATx201, ATx201 Placebo Gel; Drug
Lead sponsor: UNION therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Complex Regional Pain Syndrome
Interventions: BRC-002, BRC-002 Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: La Jolla, California • San Diego, California

Conditions: Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction, Dyspareunia, Vulvodynia, Vestibulodynia, Arousal Disorders, Sexual, Genito-Pelvic Pain/Penetration Disorder, Female Sexual Arousal Disorder
Interventions: 5% sinecatechins ointment, Placebo, 10% sinecatechins ointment; Drug
Lead sponsor: GTO Pharmaceutical, LLC; Other
Eligibility: 20 Years to 70 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: New York, New York • Nyack, New York

Conditions: Bipolar Depression, Suicidal Ideation
Interventions: Ketamine Hydrochloride, Placebo; Drug
Lead sponsor: NeuroRx, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Hollywood, Florida • Fort Worth, Texas

Conditions: End Stage Renal Disease
Interventions: Soluble Ferric Pyrophosphate in liquid bicarbonate, Placebo: Conventional liquid bicarbonate, Erythrocyte Stimulating Agent (ESA), Intravenous (IV) Iron; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 22
States / cities: Birmingham, Alabama • Tempe, Arizona • Granada Hills, California + 17 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BCT197, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 40 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Michigan City, Indiana • Baltimore, Maryland • Milwaukee, Wisconsin

Conditions: Vitiligo
Interventions: Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 46
States / cities: Glendale, Arizona • Phoenix, Arizona • Encino, California + 35 more

Search by objective public record fields.

An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis

Evaluation of Continuous Symptom Treatment of ADHD

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye

Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1

Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)

The Effect of Nebulized Albuterol on Donor Oxygenation

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

Phase I Study of VLX-1005 in Healthy Subjects

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee

Sensitization Study of ATx201 in Healthy Volunteers

The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo